OUTLOOK THERAPEUTICS INC (OTLK) - Total Liabilities
Based on the latest financial reports, OUTLOOK THERAPEUTICS INC (OTLK) has total liabilities worth $50.77 Trillion USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
OUTLOOK THERAPEUTICS INC - Total Liabilities Trend (2014–2025)
This chart illustrates how OUTLOOK THERAPEUTICS INC's total liabilities have evolved over time, based on quarterly financial data. See OTLK working capital ratio to evaluate short-term liquidity relative to the company's equity base.
OUTLOOK THERAPEUTICS INC Competitors by Total Liabilities
The table below lists competitors of OUTLOOK THERAPEUTICS INC ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Usio Inc
NASDAQ:USIO
|
USA | $80.71 Million |
|
Bumyang Construction Co Ltd
KO:002410
|
Korea | ₩183.17 Billion |
|
Templeton Emerging Markets Investment Trust TEMIT
LSE:TEM
|
UK | GBX125.19 Million |
|
DPS Resources Bhd
KLSE:7198
|
Malaysia | RM85.56 Million |
|
Spencer's Retail Limited
NSE:SPENCERS
|
India | Rs23.09 Billion |
|
NBI Bearings Europe S.A.
MC:NBI
|
Spain | €78.46 Million |
|
Malton Bhd
KLSE:6181
|
Malaysia | RM1.07 Billion |
|
Corentec Co Ltd
KQ:104540
|
Korea | ₩90.03 Billion |
Liability Composition Analysis (2014–2025)
This chart breaks down OUTLOOK THERAPEUTICS INC's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see OTLK market cap overview.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.38 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1577369.79 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 2.73 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how OUTLOOK THERAPEUTICS INC's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for OUTLOOK THERAPEUTICS INC (2014–2025)
The table below shows the annual total liabilities of OUTLOOK THERAPEUTICS INC from 2014 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-09-30 | $50.77 Trillion | +49825230.14% |
| 2024-09-30 | $101.90 Million | +118.02% |
| 2023-09-30 | $46.74 Million | +136.16% |
| 2022-09-30 | $19.79 Million | +8.72% |
| 2021-09-30 | $18.20 Million | +7.67% |
| 2020-09-30 | $16.91 Million | -39.41% |
| 2019-09-30 | $27.90 Million | -35.25% |
| 2018-09-30 | $43.09 Million | -16.26% |
| 2017-09-30 | $51.46 Million | +78.03% |
| 2016-09-30 | $28.91 Million | -17.77% |
| 2015-09-30 | $35.15 Million | -45.30% |
| 2014-09-30 | $64.26 Million | -- |
About OUTLOOK THERAPEUTICS INC
Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other … Read more